Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethosuximide for Complex Regional Pain Syndrome (CRPS)
NCT00689585Phase 2Terminated
- Sponsor
- McGill University Health Centre
- Start
- Sep 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in complex regional pain syndrome (CRPS) comparing Placebo with Ethosuximide (2 arms). Primary endpoints: Maximum Tolerated Dose at 10 weeks and Safety Profile at 10 weeks. Started Sep 2008; status: terminated.
02
Drugs
ethosuximide
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on NCT00689585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689585.